© 2018 by BioSight Ltd.

  • LinkedIn Social Icon

Publications

logo-bloodadv.png
KOLs speak of BST-236:
Aspacytarabine (BST-236) as a potential new frontline therapy option for patients with AML that are unfit for intensive chemotherapy
An AML Global Portal interview of Dr. Selina Luger during ASH 2019
AML Global interview ASH 2019.png
BIOSIGHT logo .png